Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
New York University Langone Medical Center
mi
from
New York, NY
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Fair Oaks, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Hawaiian Gardens, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Hawaiian Gardens, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Long Beach, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Orangevale, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Orangevale, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Westlake Village, CA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Westlake Village, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis
mi
from
Denver, CO
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Atlanta, GA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Conyers, GA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Conyers, GA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigator Site
mi
from
Chicago, IL
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigator Site
mi
from
Chicago, IL
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigator Site
mi
from
Topeka, KA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Edina, MN
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Edina, MN
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Belzoni, MS
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Belzoni, MS
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Jackson, MS
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis
mi
from
New York, NY
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Oregon City, OR
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Oregon City, OR
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis
mi
from
Portland, OR
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Varnville, SC
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Varnville, SC
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Richmond, VA
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated:  11/3/2015
Novartis Investigative Site
mi
from
Caba,
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Status: Enrolling
Updated: 11/3/2015
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension
Status: Enrolling
Updated:  11/3/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension
Status: Enrolling
Updated: 11/3/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Prediction of Behavior
Prediction and Pre-commitment Mailings for Medication Adherence
Status: Enrolling
Updated:  11/6/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Prediction of Behavior
Prediction and Pre-commitment Mailings for Medication Adherence
Status: Enrolling
Updated: 11/6/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention
Status: Enrolling
Updated:  11/11/2015
New York University School of Medicine
mi
from
New York, NY
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention
Status: Enrolling
Updated: 11/11/2015
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated:  11/12/2015
GSK Investigational Site
mi
from
Boston, MA
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated: 11/12/2015
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated:  11/12/2015
GSK Investigational Site
mi
from
Dallas, TX
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated: 11/12/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated:  11/12/2015
GSK Investigational Site
mi
from
Rosario,
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Status: Enrolling
Updated: 11/12/2015
GSK Investigational Site
mi
from
Rosario,
Click here to add this to my saved trials
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study
Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study
Status: Enrolling
Updated:  11/15/2015
Emory University
mi
from
Atlanta, GA
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study
Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study
Status: Enrolling
Updated: 11/15/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated:  11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated: 11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients
A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfish® in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients
Status: Enrolling
Updated:  11/16/2015
Yale Medical School
mi
from
New Haven, CT
IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients
A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfish® in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients
Status: Enrolling
Updated: 11/16/2015
Yale Medical School
mi
from
New Haven, CT
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of Arizona
mi
from
Tucson, AZ
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of California, Los Angeles - Pulmonary Division
mi
from
Los Angeles, CA
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of California, Los Angeles - Pulmonary Division
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of California, Davis Medical Center
mi
from
Sacramento, CA
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of Rochester Medical Center, Mary Parkes Center
mi
from
Rochester, NY
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of Rochester Medical Center, Mary Parkes Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
The Carl and Edyth Lindner Research Center at The Christ Hospital
mi
from
Cincinnati, OH
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
The Carl and Edyth Lindner Research Center at The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of Cincinnati
mi
from
Cincinnati, OH
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
Ohio State University Medical Center
mi
from
Columbus, OH
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated:  11/24/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension
Status: Enrolling
Updated: 11/24/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Penn Lifestyle Modification and Blood Pressure Study
Cardiovascular Effects of Iyengar Yoga vs. Enhanced Usual Care in Patients With High-normal to Stage I Hypertension
Status: Enrolling
Updated:  11/24/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
The Penn Lifestyle Modification and Blood Pressure Study
Cardiovascular Effects of Iyengar Yoga vs. Enhanced Usual Care in Patients With High-normal to Stage I Hypertension
Status: Enrolling
Updated: 11/24/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
Status: Enrolling
Updated:  11/25/2015
HealthPartners Medical Group
mi
from
Minneapolis, MN
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
Status: Enrolling
Updated: 11/25/2015
HealthPartners Medical Group
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Improving Adherence to Blood Pressure Guidelines
Improving Adherence to Blood Pressure Guidelines
Status: Enrolling
Updated:  11/30/2015
University of Iowa College of Pharmacy
mi
from
Iowa City, IA
Improving Adherence to Blood Pressure Guidelines
Improving Adherence to Blood Pressure Guidelines
Status: Enrolling
Updated: 11/30/2015
University of Iowa College of Pharmacy
mi
from
Iowa City, IA
Click here to add this to my saved trials
Multilevel Intervention for Physical Activity in Retirement Communities
MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities
Status: Enrolling
Updated:  12/1/2015
The University of California, San Diego
mi
from
La Jolla, CA
Multilevel Intervention for Physical Activity in Retirement Communities
MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities
Status: Enrolling
Updated: 12/1/2015
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Dose-Ranging Study of the Bimatoprost Ocular Insert
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  12/1/2015
Sall Medical Research Center
mi
from
Artesia, CA
Dose-Ranging Study of the Bimatoprost Ocular Insert
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 12/1/2015
Sall Medical Research Center
mi
from
Artesia, CA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Status: Enrolling
Updated:  12/2/2015
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Status: Enrolling
Updated: 12/2/2015
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Status: Enrolling
Updated:  12/2/2015
Wilmax Clinical Research, Inc.
mi
from
Mobile, AL
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Status: Enrolling
Updated: 12/2/2015
Wilmax Clinical Research, Inc.
mi
from
Mobile, AL
Click here to add this to my saved trials